Lakefront Biotherapeutics (LKFT) vs Palvella Therapeutics (PVLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Lakefront Biotherapeutics (LKFT) over the past year, gaining 75.5% versus a loss of 14.5%. Over five years, LKFT leads with a -44.9% price change compared with -63.6% for PVLA. Palvella Therapeutics is the larger company by market cap ($2.00 billion vs $1.95 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LKFT | PVLA |
|---|---|---|
| Share price | $29.73 | $138.77 |
| Market cap | $1.95B | $2.00B |
| 1-day change | +0.75% | +5.66% |
| YTD return | -9.76% | +25.48% |
| 1-year return | -14.46% | +75.47% |
| 5-year return | -44.86% | -63.60% |
| P/E ratio (TTM) | 2.83 | — |
| EPS (TTM) | $10.52 | $-4.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-41.72M |
| 52-week high | $36.24 | $161.38 |
| 52-week low | $25.68 | $65.93 |
| Distance from 52-week high | -17.96% | -14.01% |
| Analyst consensus | hold | none |
| Avg. price target upside | +1.51% | +66.12% |
| Average volume | 273.30K | 211.36K |
| Shares outstanding | 65.48M | 14.41M |
| Employees | 196 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed LKFT by 89.9 percentage points over the past year.
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
LKFT vs PVLA FAQ
Which is bigger, Lakefront Biotherapeutics or Palvella Therapeutics?
Palvella Therapeutics (PVLA) is larger, with a market capitalization of $2.00B compared with $1.95B for Lakefront Biotherapeutics (LKFT).
Which stock has performed better over the past year, LKFT or PVLA?
PVLA returned +75.47% over the past 12 months, compared with -14.46% for LKFT (price return, excluding dividends). Past performance does not predict future results.
Are Lakefront Biotherapeutics and Palvella Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.